Skip to main content
TARS logo
TARS
(NASDAQ)
Tarsus Pharmaceuticals, Inc.
$70.12-- (--)
Loading... - Market loading

Tarsus Pharmaceuticals (TARS) Balance Sheet

Assets, liabilities, and shareholders' equity with annual and quarterly data.

Tarsus Pharmaceuticals Balance Sheet Analysis

Assets, liabilities, and stockholders equity in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Tarsus Pharmaceuticals, Inc. (TARS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Current Assets
Cash and Cash Equivalents183.6494.82224.9571.66171.33168.1357.952.36
Short-Term Investments233.63196.562.50145.370.480.000.000.00
Cash & Short-Term Investments417.27291.38227.44217.03171.82168.1357.952.36
Accounts Receivable87.1148.0617.713.580.090.020.040.00
Inventory4.372.623.110.000.000.000.000.00
Other Current Assets13.4714.657.874.774.052.510.040.02
Total Current Assets522.78356.71256.13225.38175.95170.6658.032.38
Non-Current Assets
Property, Plant & Equipment (Net)21.752.873.351.531.831.240.280.01
Long-Term Investments3.873.000.860.370.000.000.000.00
Intangible Assets7.378.333.870.000.000.000.000.00
Other Non-Current Assets6.406.091.290.590.390.080.010.00
Total Non-Current Assets39.3820.299.362.492.961.320.290.01
Total Assets562.16376.99265.49227.86178.91171.9758.322.39
Current Liabilities
Accounts Payable16.3927.7417.775.502.862.240.460.18
Short-Term Debt0.000.610.400.721.310.280.060.00
Accrued Liabilities26.8819.1413.909.217.210.000.000.00
Other Current Liabilities90.6252.274.879.207.262.870.300.00
Total Current Liabilities135.7080.6136.9415.4311.485.390.820.18
Non-Current Liabilities
Long-Term Debt72.4471.8529.8219.430.590.550.100.00
Other Non-Current Liabilities-10.600.001.750.100.110.0663.403.56
Total Non-Current Liabilities83.0471.8531.5719.530.700.6163.503.56
Total Liabilities218.73152.4668.5034.9612.185.9964.323.74
Stockholders' Equity
Common Stock0.010.010.010.010.000.000.000.00
Retained Earnings-426.63-360.21-244.66-108.76-46.67-32.85-6.03-1.36
Accumulated Other Comprehensive Income0.380.180.00-0.070.000.000.000.00
Additional Paid-in Capital769.67584.56441.64301.73213.40198.820.03-3.56
Shares Outstanding42.5538.3534.2126.7320.700.000.000.00
Total Stockholders' Equity343.43224.53196.99192.90166.73165.98-6.01-1.35
Total Liabilities & Equity562.16376.99265.49227.86178.91171.9758.322.39

Frequently Asked Questions About Tarsus Pharmaceuticals Balance Sheet

What is a balance sheet?

A balance sheet shows a company's financial position at a specific point in time. It lists total assets (what the company owns), total liabilities (what it owes), and stockholders' equity (the difference). The fundamental equation: Assets = Liabilities + Equity.

What is stockholders' equity?

Stockholders' equity represents the net value belonging to shareholders — total assets minus total liabilities. It includes retained earnings, common stock, and additional paid-in capital. Growing equity over time typically indicates a healthy, profitable business.

What is working capital?

Working capital is current assets minus current liabilities. It measures a company's ability to pay short-term obligations with short-term assets. Positive working capital indicates the company can cover its near-term debts; negative may signal liquidity risk.

What is TARS's debt level?

Review Tarsus Pharmaceuticals's total long-term debt and short-term borrowings in the balance sheet table above. Compare debt to equity and total assets to assess leverage and financial risk.

What is book value per share?

Book value per share is total stockholders' equity divided by shares outstanding. It represents the accounting value per share if the company were liquidated. Comparing market price to book value gives the price-to-book (P/B) ratio — a key valuation metric.

These financial metrics are calculated using balance sheet data. Learn how each metric works and screen stocks by them.